Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

ASCO Lung Cancer Roundtable - NSCLC - The SINDAS Trial: Addition of SBRT to a Systemic TKI for EGFR
Author
Howard (Jack) West, MD
Image
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.

Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon.

Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic is Trial Updates - NSCLC and the SINDAS Trial - The Addition of SBRT to a Systemic EGFR inhibitor (TKI) in EGFR positive NSCLC.

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
2025-26 Clinical Trials Storytelling
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Watch the Webinar Now ON Demand
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.   ¡Los vídeos están disponibles BAJO DEMANDA! Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.